Title:
SARS-COV-2 SUBUNIT VACCINE
Document Type and Number:
WIPO Patent Application WO/2022/233630
Kind Code:
A3
Abstract:
The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the S1 subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.
More Like This:
Inventors:
BARREIRO VAZQUEZ ANTONIO (ES)
PRENAFETA AMARGOS ANTONI (ES)
FERRER SOLER LAURA (ES)
GONZALEZ GONZALEZ LUIS (ES)
PUIGVERT MOLAS ESTER (ES)
PALMADA COLOMER JORDI (ES)
PRAT CABAÑAS MARIA TERESA (ES)
GARRIGA ALSINA CARMEN (ES)
PRENAFETA AMARGOS ANTONI (ES)
FERRER SOLER LAURA (ES)
GONZALEZ GONZALEZ LUIS (ES)
PUIGVERT MOLAS ESTER (ES)
PALMADA COLOMER JORDI (ES)
PRAT CABAÑAS MARIA TERESA (ES)
GARRIGA ALSINA CARMEN (ES)
Application Number:
PCT/EP2022/060942
Publication Date:
December 15, 2022
Filing Date:
April 25, 2022
Export Citation:
Assignee:
HIPRA SCIENT S L U (ES)
LABORATORIOS HIPRA S A (ES)
LABORATORIOS HIPRA S A (ES)
International Classes:
A61K39/12; A61K39/295; A61P31/14
Foreign References:
| US10953089B1 | 2021-03-23 | |||
| CN111944064A | 2020-11-17 | |||
| CN112089831B | 2021-04-02 |
Other References:
DAI LIANPAN ET AL: "A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS", CELL, ELSEVIER, AMSTERDAM NL, vol. 182, no. 3, 28 June 2020 (2020-06-28), pages 722, XP086239965, ISSN: 0092-8674, [retrieved on 20200628], DOI: 10.1016/J.CELL.2020.06.035
POLLET JEROEN ET AL: "Recombinant protein vaccines, a proven approach against coronavirus pandemics", ADVANCED DRUG DELIVERY REVIEWS, vol. 170, 1 March 2021 (2021-03-01), Amsterdam , NL, pages 71 - 82, XP055824752, ISSN: 0169-409X, DOI: 10.1016/j.addr.2021.01.001
POLLET JEROEN ET AL: "SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice", BIORXIV : THE PREPRINT SERVER FOR BIOLOGY, 5 November 2020 (2020-11-05), United States, XP055824766, Retrieved from the Internet [retrieved on 20210715], DOI: 10.1101/2020.11.04.367359
JINKAI ZANG ET AL: "Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement", CELL DISCOVERY, vol. 6, no. 1, 3 September 2020 (2020-09-03), XP055734434, DOI: 10.1038/s41421-020-00199-1
CHAPPELL KEITH J ET AL: "Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial", THE LANCET INFECTIOUS DISEASES, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 10, 19 April 2021 (2021-04-19), pages 1383 - 1394, XP086792674, ISSN: 1473-3099, [retrieved on 20210419], DOI: 10.1016/S1473-3099(21)00200-0
GUPTA TANIA ET AL: "Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 86, 18 June 2020 (2020-06-18), XP086247463, ISSN: 1567-5769, [retrieved on 20200618], DOI: 10.1016/J.INTIMP.2020.106717
BAYAT MARYAM ET AL: "Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 97, 15 April 2021 (2021-04-15), XP086705619, ISSN: 1567-5769, [retrieved on 20210415], DOI: 10.1016/J.INTIMP.2021.107679
AN YALING ET AL: "A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates", BIORXIV, 11 March 2021 (2021-03-11), XP055884118, Retrieved from the Internet [retrieved on 20220126], DOI: 10.1101/2021.03.11.434928
POLLET JEROEN ET AL: "Recombinant protein vaccines, a proven approach against coronavirus pandemics", ADVANCED DRUG DELIVERY REVIEWS, vol. 170, 1 March 2021 (2021-03-01), Amsterdam , NL, pages 71 - 82, XP055824752, ISSN: 0169-409X, DOI: 10.1016/j.addr.2021.01.001
POLLET JEROEN ET AL: "SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice", BIORXIV : THE PREPRINT SERVER FOR BIOLOGY, 5 November 2020 (2020-11-05), United States, XP055824766, Retrieved from the Internet
JINKAI ZANG ET AL: "Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement", CELL DISCOVERY, vol. 6, no. 1, 3 September 2020 (2020-09-03), XP055734434, DOI: 10.1038/s41421-020-00199-1
CHAPPELL KEITH J ET AL: "Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial", THE LANCET INFECTIOUS DISEASES, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 10, 19 April 2021 (2021-04-19), pages 1383 - 1394, XP086792674, ISSN: 1473-3099, [retrieved on 20210419], DOI: 10.1016/S1473-3099(21)00200-0
GUPTA TANIA ET AL: "Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 86, 18 June 2020 (2020-06-18), XP086247463, ISSN: 1567-5769, [retrieved on 20200618], DOI: 10.1016/J.INTIMP.2020.106717
BAYAT MARYAM ET AL: "Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 97, 15 April 2021 (2021-04-15), XP086705619, ISSN: 1567-5769, [retrieved on 20210415], DOI: 10.1016/J.INTIMP.2021.107679
AN YALING ET AL: "A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates", BIORXIV, 11 March 2021 (2021-03-11), XP055884118, Retrieved from the Internet
Attorney, Agent or Firm:
HOFFMANN EITLE S.L.U. (ES)
Download PDF: